Journal: Frontiers in Neuroscience

Article Title: Histological analysis of thrombus composition in acute ischemic stroke with large vessel occlusion: impact of r-tPA treatment

doi: 10.3389/fnins.2025.1707934

Figure Lengend Snippet: Comparison of three staining methods in different TOAST classification. We selected three representative thrombus slice samples and observed them under 100x and 400x magnification. By selecting a representative region and magnifying it 400 times. In HE staining, red represents RBC, blue represents WBC, and the rest are PLT + FIB complexes. In IHC staining, in CD61, brown indicates PLT, blue indicates WBC, and the rest are other complexes; in FGB, brown indicates FIB, blue indicates WBC, and the rest are other complexes; We found that fibrin was present in the areas rich in red blood cells. LAA, large-artery atherosclerosis; CE, cardiogenic embolism; SUE, stroke of undetermined etiology; CD61, cluster of differentiation 61; IHC, immunohistochemistry; RBC, red blood cell; PLT, platelet; FIB, fibrin; Original magnification: 100×, Scale bar = 200 μm; Total magnification: 400×, Scale bar = 50 μm.

Article Snippet: The following steps were then carried out in sequence: (1) Antigen retrieval specific to the tissue (preventing excessive evaporation of the buffer solution and avoiding dry sections); (2) Blocking with 3% H2O2 (25 min, protected from light); (3) Blocking with serum (30 min, at room temperature); (4) Incubation with primary antibody CD61 (integrin β3, 66,952-1-ig, Proteintech, 1:1000) overnight at 4 °C; (5) Incubation with HRP-labeled secondary antibody (Anti-FGB Antibody, M01204-1, BOSTER, 1:200) for 50 min at room temperature; (6) Color development with DAB chromogen from the immunohistochemical kit followed by washing with water to stop the reaction; (7) Counterstaining with hematoxylin (3 min) and bluing with hematoxylin bluing solution; (8) Dehydration through a gradient of alcohol and clearing with xylene; (9) Mounting with neutral gum; (10) Analysis under an optical microscope.

Techniques: Comparison, Staining, Immunohistochemistry

Journal: Materials Today Bio

Article Title: Synergistic exacerbation of periprosthetic osteolysis by inflammatory bowel disease and titanium ions: Impaired osteogenesis of BMSCs via PI3K/AKT signaling

doi: 10.1016/j.mtbio.2025.102236

Figure Lengend Snippet: Breakdown of intestinal mucosal physical barrier and immune barrier in UC Rat models. (A) Representative immunofluorescence staining of α-SMA, Vinculin and CD61 associated with tight junctions in colon tissue and (C, D, E) their relative fluorescence intensity. (B) Representative immunofluorescence staining of iNOS, CD206 and CD68 associated with macrophage typing in colon tissue and (F, G) their relative fluorescence intensity. Scale bar = 200 μm. Data represented as mean ± SD (error bars) (C, D, E, F, G) from biological replicates. ns: not significant, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

Article Snippet: Specifically, consecutive sections were permeated with 0.1 % TritonX-100 for 20 min. For tight junction protein, using anti-α-SMA antibody (1:200, 67735-1-Ig, Proteintech), anti-Vinculin antibody (1:200, 66305-1-Ig, Proteintech), and anti-CD61 antibody (1:200, 18309-1-AP, Proteintech); For osteogenic indicators, using anti-Runx2 antibody (1:200, 20700-1-AP, Proteintech), anti-Sp7 antibody (1:200, ab209484, Abcam), and OPN antibody (1:200, 22952-1-AP, Proteintech); For macrophage markers, using anti-iNOS antibody (1:200, 18985-1-AP, Proteintech), anti-CD206 antibody (1:200, 18704-1-AP, Proteintech), and anti-CD68 antibody (1:200, 28058-1-AP) to incubate with samples, followed by incubation with the fluorescently labeled secondary antibody and DAPI.

Techniques: Immunofluorescence, Staining, Fluorescence

Journal: iScience

Article Title: Targeting CCR5 with miltefosine as a therapeutic strategy for thrombocytopenia

doi: 10.1016/j.isci.2025.112379

Figure Lengend Snippet: Miltefosine promotes MK differentiation and maturation in K562 and HEL cells (A) Flow cytometric analyses of proportion of CD41 + CD42b + cells in K562 and HEL cells treated with miltefosine (10, 20, and 40 μM) or PMA (0.8 nM) for 5 days. (B) Flow cytometric analyses of proportion of CD41 + CD61 + cells of each group. (C) DNA ploidy of each group. (D) Quantification of the percentage of CD41 + CD42b + cells in K562. n = 3. (E) Quantification of the percentage of CD41 + CD42b + cells in HEL. n = 3. (F) Quantification of the percentage of CD41 + CD61 + cells in K562. n = 3. (G) Quantification of the percentage of CD41 + CD61 + cells in HEL. n = 3. (H) Quantification of the DNA ploidy in K562. n = 3. (I) Quantification of the DNA ploidy in HEL. n = 3. Statistical significance in (D–I) was calculated using a one-way analysis of variance (ANOVA) test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, vs. control group. Error bars represent mean ± SD.

Article Snippet: CD61 (Integrin beta 3) Monoclonal Antibody , Thermo Fisher Scientific , Cat# 12-0619-42.

Techniques: Control

Journal: iScience

Article Title: Targeting CCR5 with miltefosine as a therapeutic strategy for thrombocytopenia

doi: 10.1016/j.isci.2025.112379

Figure Lengend Snippet: Miltefosine stimulates hematopoietic recovery in RIT mice (A) H&E staining of BM from control, model, TPO (3000 U/kg), and miltefosine (10, 20, and 40 mg/kg)-treated groups on day 10. Scale bar: 50 μM. (B) Quantification of MK counts in BM across groups. n = 3. (C) Immunohistochemical analysis for CD41 in BM. Scale bar, 50 μM. (D) Quantification of CD41-positive MKs in BM. n = 3. (E) H&E staining of spleen in each group. Scale bar, 50 μM. (F) Quantification of MK counts in spleen across groups. n = 3. (G and H) Flow cytometric analysis and quantification of c-Kit + CD41 + cells in BM. n = 3. (I and J) Flow cytometric analysis and quantification of CD41 + CD42d + cells in BM. n = 3. (K and L) Flow cytometric analysis and quantification of CD41 + CD42d + cells in spleen. n = 3. (M and N) Flow cytometric analysis and quantification of CD41 + CD61 + cells in BM. n = 3. (O and P) Flow cytometric analysis and quantification of CD41 + CD61 + cells in spleen. n = 3. (Q and R) Flow cytometric analysis and quantification of DNA ploidy in BM. n = 3. (S and T) Flow cytometric analysis and quantification of DNA ploidy in spleen. n = 3. Statistical significance in (B,D,F,H,J,L,N,P,R,T) was calculated using a one-way ANOVA test. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, vs. model group. Error bars represent mean ± SD.

Article Snippet: CD61 (Integrin beta 3) Monoclonal Antibody , Thermo Fisher Scientific , Cat# 12-0619-42.

Techniques: Staining, Control, Immunohistochemical staining

Journal: iScience

Article Title: Targeting CCR5 with miltefosine as a therapeutic strategy for thrombocytopenia

doi: 10.1016/j.isci.2025.112379

Figure Lengend Snippet:

Article Snippet: CD61 (Integrin beta 3) Monoclonal Antibody , Thermo Fisher Scientific , Cat# 12-0619-42.

Techniques: Recombinant, Lysis, CCK-8 Assay, Staining, Membrane, Western Blot, Software

Journal: iScience

Article Title: Inflammation-responsive biomimetic nanoparticles with epigallocatechin-3-gallate for acute lung injury therapy via autophagy enhancement

doi: 10.1016/j.isci.2025.112318

Figure Lengend Snippet:

Article Snippet: CD61 Antibody , Proteintech , Cat # 18309-1-AP; RRID: AB_2128759.

Techniques: Recombinant, Software